LLLe Thi Tuyet Lan

Le Thi Tuyet Lan

*This is an algorithmically generated author record based on publicly available information.

Le Thi Tuyet Lan has a total of 271 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

    by J. Bousquet, E. Melén, T. Haahtela, G. H. Koppelman, A. Togias, R. Valenta, C. A. Akdis, W. Czarlewski, M. Rothenberg, A. Valiulis, et al.

    Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.


  • Open Access

    Stepping down for mild asthma and disadvantages of the ‘as‐needed’ strategy—Perspectives from a developing country

    by Lam Nguyen‐Ho, Vinh Nguyen‐Nhu, Chang Yoon‐Seok, Anh‐Tuan Dinh‐Xuan, Tuyet‐Lan Le‐Thi


  • Open Access

    Stepping down therapy for well-controlled mild asthma: an experience from University Medical Center at Ho Chi Minh City

    by Nguyen-Ho Lam, Nguyen-Thanh Nam, Le-Thuong Vu, Nguyen-Nhu Vinh, Le-Thi Tuyet-Lan

    Background: Stepping down treatment for well-controlled mild asthma is challenging to clinicians. The step-down strategy using regularly-intermittent low-dose inhaled corticosteroid has been applied at the University Medical Center (UMC) of Ho Chi Minh City, called as “UMC” approach. Objective: This study aimed to evaluate the efficiency of UMC step-down strategy in well- controlled mild asthma. Methods: A real-world retrospective descriptive study was conducted at UMC from 2009 to 2018. All asthmatic patients (age ≥ 12) who received step-down therapy using this UMC approach were evaluated. Results: Among 2,072 asthma patients to be treated with UMC step-down strategy, only 112 subjects were eligible. The median age was 38.5 years and female was 62.5%. Most patients at their initial presentation were indicated step 4 treatment (87.5%). The controller medications before initiation of UMC treatment included fluticasone propionate 125 μg once-daily, salmeterol/fluticasone propionate 25/125 μg once-daily, and formoterol/budesonide 4.5/160 μg once-daily. After being treated with the UMC approach, the rates of well-controlled asthma ranged from 67.6% to 91.1%. During 1 year with UMC treatment, pulmonary function remained stable and only 7 subjects (6.3%) developed exacerbation. Conclusion: The UMC step-down treatment for well-controlled mild asthma was relatively efficient in maintaining asthma control, stabilization of pulmonary function, and reducing risk of severe exacerbation.


  • Open Access

    Asia Pacific Association of Allergy Asthma and Clinical Immunology White Paper 2020 on climate change, air pollution, and biodiversity in Asia-Pacific and impact on allergic diseases

    by Ruby Pawankar, Jiu-Yao Wang, I-Jen Wang, Francis Thien, Yoon-Seok Chang, Amir Hamzah Abdul Latiff, Takao Fujisawa, Luo Zhang, Bernard Yu-Hor Thong, Pantipa Chatchatee, et al.

    Pawankar R, et al. Asia Pac Allergy. 2020 Jan;10(1):e11. https://doi.org/10.5415/apallergy.2020.10.e11